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Introduction
Inhibitors of the DNA damage response (DDR) offer an exciting opportunity to identify targeted cancer therapies (1) (2) (3) . In addition to enhancing the effectiveness of DNA-damaging chemotherapies and ionizing radiation (IR) treatment, DDR-inhibitors have the potential for single-agent activity in specific tumor genetic backgrounds based on the principle of synthetic lethality (4) . This was first exemplified by inhibitors of the DDR protein poly(ADPribose) polymerase (PARP) in Breast Cancer Associated (BRCA)-deficient genetic backgrounds that are associated with a high lifetime risk of breast and ovarian cancer (5, 6) .
The mechanism for this single-agent activity has been linked to the role of PARP in the repair of DNA single-strand breaks (SSBs) (7, 8) and DNA double-strand breaks (DSBs) (9, 10) .
Following inhibitor treatment, PARP is trapped onto the unrepaired SSB, resulting in a protein-DNA adduct (11) that impedes replication fork progression, leading to replication fork collapse and the generation of the more genotoxic DSBs. These DSBs would normally be repaired by the homologous recombination repair (HRR) pathway (12) , in which both BRCA1 and BRCA2 genes play pivotal roles (13) . However, in tumors with HRR-defective backgrounds (e.g. because of BRCA deficiency), error-prone DNA repair pathways are utilized instead (9, 10, 14) , resulting in the accumulation of genomic instability, chromosomal aberrations, and subsequently, cancer cell death. As a patient's normal tissue ordinarily has a functional HRR pathway, this results in tumor-specific cell killing.
Olaparib (AZD2281) is an oral and potent inhibitor of PARP activity (15) and the first PARP inhibitor to gain regulatory approval (16) , (17) . Olaparib demonstrates low nanomolar activity against PARP1 and PARP2 enzymes and only weak enzyme activity against tankyrase-1 (15). The vast majority of poly(ADP) ribosylation that can be detected in 6 mammalian cells is attributed to PARP1 (18) , the key PARP protein involved in SSB repair, with PARP2 recognizing gaps and flap structures (19) .
Olaparib has demonstrated single-agent anti-tumor activity in patients with both BRCAmutant ovarian (20) and breast cancer (21) , as well as in the broader serous ovarian cancer patient population, where patients who do not harbor BRCA mutations have also gained clinical benefit from single-agent olaparib treatment (22, 23) . In this latter study, olaparib demonstrated a significant increase in progression-free survival (PFS) compared with placebo in patients with high-grade serous ovarian cancer in a maintenance setting. Olaparib was very well tolerated as a single agent and cessation of treatment was due primarily to tumor progression, most likely as a consequence of emerging tumor resistance.
Currently, there is a paucity of data around resistance mechanisms associated with olaparib in the clinical setting. Preclinically, resistance mechanisms that have been identified in BRCAdeficient tumors include the reactivation of BRCA2 gene reading frames by secondary mutations (24) ; the loss of 53BP1 (25, 26) or REV7 (27) in BRCA1;p53-deficient cancer cells, and the over-expression of the Abcb1a and Abcb1b genes encoding the mouse drug efflux transporter P-glycoprotein (P-gp), for which olaparib is a substrate. This last mechanism has been described in both BRCA1;p53-deficient (28) and BRCA2;p53-deficient (29) mouse mammary tumors. While the clinical significance of P-gp-based resistance for olaparib is still not clear, it may be of relevance in some cancers that are more commonly associated with high P-gp levels, e.g. colorectal cancers and acute leukemias.
Here, we characterize a second-generation PARP inhibitor, AZD2461, derived from the same chemical series as olaparib, which retains the same level of anti-cancer cell potency (in vitro and in vivo) but is differentiated from olaparib in terms of sensitivity to drug resistance mechanisms and PARP inhibitor profile.
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Materials and Methods
Olaparib and AZD2461 PARP inhibitor compounds
The PARP inhibitor olaparib (AZD2281, KU-59436) has been described previously (15) .
AZD2461 synthesis is described in the international patent WO2009/093032, specifically compound numbers 2b and 47. Formulation of compounds for in vivo studies is provided in Suppl Materials and Methods.
Cell line and culture methods
Human lung carcinoma A549 cells, breast cancer cell lines MDA-MB-436, T47D, BT549, MDA-MB231, SUM1315MO2, and SUM149PT, cervical cell lines HeLa, were grown in culture media conditions described in Suppl Materials and Methods. BRCA1 mutation status of breast cell lines has been described previously (30) .
Alkaline comet assay
A549 cells were pre-treated for 1 hour at 37âC with 0.05% dimethyl sulfoxide (DMSO), olaparib, or AZD2461 (500 nM). Cells were treated with 30 Gy -IR (on ice) and allowed to recover at 37âC for the indicated time. SSBs (tail moments) were analyzed by alkaline comet assay as described (31) . Comet tail moments were scored from 100 cells per experiment using Comet Assay IV (Perceptive Instruments). Two-way analysis of variance was carried out on the mean values for each time point from replicate experiments.
Immunofluorescence
For -H2AX analysis, A549 cells on cover slips were pre-incubated for 1 hour with DMSO or PARP inhibitors, and then irradiated (2Gy). The cells were incubated at 37ºC for the times 8 stated to allow repair. Cells were then immunostained for -H2AX foci, which were counted microscopically. For more details see Suppl Materials and Methods.
PARP1, PARP2, and tankyrase isolated enzyme in vitro assays
The activity (IC50) of PARP inhibitors was assessed against purified PARP1, PARP2, and tankyrase enzymes in vitro as described (15) .
PARP3 Bio-NAD in vitro assay
PARP3 protein was prepared as described (32) . A detailed protocol of the assay is described in Suppl Materials and Methods. In short, the ribosylation reaction mix was incubated with Bio-NAD+ (Trevigen) and Sau3A-cut peGFP-C1 plasmid (Clontech). Products were separated by SDS-PAGE, blotted onto nitrocellulose membrane, and signal detected using Streptavidin-HRRP (GE Healthcare).
Clonogenic and cell proliferation assays
Cells were detached from the flask using trypsin and washed with medium. The pellet was dislodged in growth medium into a single-cell suspension and counted in Nucleocounter. 
Rodent experiments
Brca1 5-13/ 5-13 ;p53 2-10/ 2-10 mammary tumors were generated in K14cre;Brca1 F5-13/F5-13 ;p53 F2-10/F2-10 mice and genotyped as described (33) 
RNA isolation and RT-PCR
Total RNA was extracted from fresh bone marrow of six individual mice (CD-1 Nude Foxn1 nu ), six rats (HsdHan:RNU-Foxn1 rnu ), and human bone marrow mononuclear cells from six different individuals (Lonza 2M-125C) using RNeasy Mini kit (Qiagen) according to manufacturers' instructions. To remove potential DNA contamination, the samples were DNase treated (RNase-Free DNase Set, Qiagen). RNA purity and concentration were determined spectrophotometrically (260/280 >1.9). RNA integrity was assessed on an Agilent 2100 Bioanalyzer using RNA 6000 Nano Chip.
Human, rat, and mouse PARP1, 2, and 3 sequences were aligned using the Megalign module in DNAstar to facilitate design of primers and probes for both TaqMan and SYBR green qRT-PCR assays in areas of sequence identity. All sequences were also blast searched using the BLAST tool from the NCBI website to ensure target specificity. Assay efficiencies were calculated for each primer set to ensure template DNA from all species were amplified 11 similarly. Primers and probes were custom or catalogue ordered from Life Technologies (Invitrogen). Sequences are listed in Suppl Materials and Methods.
Results and Discussion
Generation of the novel PARP inhibitor AZD2461 as a follow on to olaparib
Based on emerging preclinical resistance data, we set about identifying a compound of similar efficacy to olaparib but without the potential liability associated with being a substrate for the P-gp (MDR1) transporter. Triaging of compounds following medicinal chemistry (see Suppl Materials and Methods) identified two series of compounds around the phthalazinone core of olaparib. AZD2461 (Fig. 1A) was identified as the optimal compound from the Piperidine Ether series (see international patent WO2009/093032, specifically compound number 2b and 47) and is a potent inhibitor of both PARP1 and PARP2 having enzyme IC50 values of 5 nM and 2 nM, respectively, comparable to that of olaparib (5 nM and 1 nM, respectively). The lack of selectivity between PARP1 and PARP2 may be considered a positive feature when attempting to inhibit SSB repair, as PARP2 also plays an important role in this pathway (34) . To confirm that AZD2461 is as effective at inhibiting SSB repair as olaparib, we compared the ability of both compounds to inhibit the formation of cellular poly (ADP-ribose) (PAR) polymers following treatment with 10 mM hydrogen peroxide. AZD2461, like olaparib, was effective at inhibiting PAR formation in these assays (Suppl Fig. 1 ). To confirm that observed PAR inhibition translated into inhibition of SSB repair, we employed the alkaline COMET assay, where the length of the comet tail moment represents the degree of unrepaired SSBs following the induction of DNA damage by IR (Fig. 1B) . We were also able to demonstrate that AZD2461 potentiated the anti-proliferation effect of the DNA-damaging alkylating agent methyl methanesulfonate (MMS), which induces SSBs ( (Fig. 1D) An assessment of in vitro permeability and efflux of AZD2461 was undertaken in the human intestinal-derived cell line CaCo-2 (see Suppl Materials and Methods and Suppl Table 2) and in the matched cell lines KBA1, a genetically modified version of HeLa that overexpresses high levels of P-gp (35) , and KB31, which does not over-express P-gp ( Fig. 2A) .
While this functional assay does not distinguish between saturation of the P-gp pumps versus low binding, it does allow discrimination between compounds that are highly effluxed and those that are not. Using these two assays, we were able to distinguish low versus highly effluxed compounds, while addition of the P-gp inhibitor verapamil provided further evidence that efflux was occurring through a P-gp mechanism. The data in Fig. 2A show that, in contrast to olaparib, AZD2461 has similar activity between KBA1 cells and matched WT KB31 cells. Moreover, the addition of verapamil to KBA1 cells showed very little effect on the cellular activity of AZD2461, which indicated that AZD2461 is significantly less prone to the P-gp-mediated efflux mechanisms than olaparib. Similar data supporting a lack of P-gp liability were obtained in the colorectal cancer cell line HCT-15, which is characterized by high levels of endogenous Pg-P expression (Suppl Fig. 3 and Suppl Table 3 ).
To assess AZD2461 activity in the more clinically relevant BRCA-mutant background and acquired resistant setting, we used in vitro and in vivo models where prolonged treatment 14 with olaparib had led to resistance and high levels of P-gp expression. The BRCA2-deficient mouse breast cancer line KB2P3.4 was generated from a BRCA2-deficient mouse mammary tumor that demonstrated sensitivity to olaparib treatment (36) . The KB2P3.4 cell line was treated in culture with olaparib for 2 months in order to induce the olaparib-resistant line KB2P3.4R, and over-expression of Pg-P was confirmed using immunofluorescence with a Pgp antibody (Fig. 2B) . Treatment of the parental KB2P3.4 with AZD2461 resulted in a similar response to olaparib (Fig. 2B) . However, unlike olaparib, AZD2461 was also effective in the high P-gp-expressing KB2P3.4R cell line. Consistent with this difference being based on P-gp, the olaparib sensitivity in KB2P3.4R cells was restored on co-treatment with tariquidar, a new generation P-gp inhibitor.
Increased expression of the Abcb1a and Abcb1b genes encoding the mouse drug efflux transporter P-gp contributes to olaparib resistance in BRCA1;p53-deficient mouse mammary tumors (28) . To determine whether AZD2461 could overcome olaparib resistance in vivo, small tumor fragments of an olaparib-resistant tumor (T6-28) exhibiting an 80-fold increased expression of the Abcb1b gene were transplanted orthotopically into syngeneic WT female mice. When the tumor volume reached about 200 mm 3 , the animals were treated with olaparib, combination of olaparib with the P-gp inhibitor tariquidar, or with AZD2461. As expected, olaparib resistance was successfully overcome by tariquidar pre-treatment (Fig.   2C) . We also found that these tumors were sensitive to AZD2461 without the need for additional tariquidar treatment, consistent with the idea that spontaneous BRCA1;p53-defective mammary tumors, in which resistance is caused by increased P-gp-mediated drug efflux, remain sensitive to AZD2461. Consistent with these findings, in a separate study, long-term AZD2461 treatment in the BRCA1;p53-defective mouse tumor model suppressed the development of drug resistance (37) . 15 Together, these data demonstrate that AZD2461 is a potent inhibitor of PARP1 and PARP2 that can provide effective inhibition of SSB repair and has significant single-agent activity in BRCA-deficient cancer cells, comparable to that of olaparib. Moreover, we have shown that AZD2461 is a poor substrate for P-gp and has activity in olaparib-resistant cancer cells that over-express P-gp in vitro and is capable of anti-tumor activity in vivo in olaparib-resistant tumors where resistance is based on the over-expression of P-gp. In this respect, the initial goal to develop a follow-on compound to olaparib that has comparable activity but without olaparib's P-gp liability has been successful. As a result, AZD2461 represents an excellent preclinical tool to study PARP inhibitor resistance, as it avoids this common mechanism of resistance and may help to identify additional mechanisms of PARP inhibitor resistance.
AZD2461 is as efficacious as, and better tolerated than, olaparib in combination with temozolomide in a mouse xenograft model
In addition to the utility of PARP inhibitors as single agents, there is also a strong rationale for combination with DNA-damaging chemotherapies such as temozolomide or camptothecins that induce SSBs (38, 39) . As a single agent, the synthetic lethality of olaparib relies on the endogenously generated SSBs and the inability of BRCA mutation or other HRR deficiency to repair the ensuing DSBs, ultimately resulting in cancer cell death. In combination with DNA-damaging chemotherapies, the number of SSBs being generated by the chemotherapy agent is much larger than those that occur endogenously (40) and if repair is prevented (e.g. by treatment with a PARP inhibitor), cell death can be induced even when the HRR pathway is functional, purely because the DNA damage threshold that can be tolerated is exceeded. This has two important implications: first, a combination of a PARP inhibitor and SSB-inducing agent can result in the killing of HRR-proficient as well as HRR-16 deficient cancer cells; second, there is also the potential for increased damage in normal tissue compartments, which is evidenced in the increased hematological toxicities observed in patients when PARP inhibitors and alkylating agents are combined (41) .
To assess AZD2461 in combination with temozolomide in vivo, we used a mouse colorectal xenograft (SW620) model to compare the anti-tumor activity of 50 mg/kg temozolomide given once daily for 5 days either alone or in combination with 10 mg/kg AZD2461 or 10 mg/kg of olaparib where the PARP inhibitors were given for 7 days. This dose and schedule of olaparib had previously demonstrated potentiation of temozolomide anti-tumor activity (Suppl Fig. 4A ). The data presented in Fig. 3A show that, as expected, temozolomide alone demonstrated anti-tumor activity and that this was improved considerably by combining with a PARP inhibitor. Statistical analysis of the results on day 55 (when the temozolomide treatment group was culled) showed that this difference was significant (p<0.001) and that the effect between the combination groups (i.e. temozolomide plus olaparib versus temozolomide plus AZD2461) was not statistically significant either at day 55 (p=0.53) or when the study was stopped at day 73 (p=0.57). Moreover, both combination treatments conferred considerable delay in tumor re-growth compared with temozolomide alone.
To examine the potential impact of AZD2461 in terms of tolerability, we looked at body weight loss as a gross indicator and at myelosuppression as a more clinically relevant indicator of combinatorial toxicity. Body weights of mice decreased relative to their weight at the start of the experiment but recovered quickly after the dosing was finished; weight loss was greater in the two combination groups (Suppl Fig. 5A ).
To assess the impact of the combinations on bone marrow populations compared with single agent chemotherapy, we took cohorts of mice and gave the same dose and regimen as used in the combination efficacy study. Mice were culled at time points across the dosing phase to create a time course in which the impact of the treatments on the bone marrow cells could be assessed ( Fig. 3B and 3C) . At the designated time points, femurs were excised and bone marrow cells flushed out and counted using flow cytometry. Using forward and side scatter parameters, three distinct white blood cell populations could be identified (lymphocytes, monocytes, and neutrophils) and these data showed that alone, temozolomide led to a reduction in the total number of white blood cells in bone marrow with the nadir after the last dose and a failure to return to the starting levels at day 8. Temozolomide in combination with olaparib led to a significantly greater impact on bone marrow (a nadir at day 6 and a worse state of recovery at day 8).
An unexpected finding, however, was that AZD2461 in combination with temozolomide did not result in the same severity of bone marrow effects as the olaparib combination. In fact, the nadir was not statistically different from temozolomide alone and there was a good recovery by day 8. Although lower doses of olaparib could result in less bone marrow toxicity, these are also likely to be less efficacious, as demonstrated by Suppl Fig. 4 , which shows that doses of 3 mg/kg of olaparib and below in combination with temozolomide (50 mg/kg) do not confer a statistically significant benefit over temozolomide alone (maximum tolerated dose 68 mg/kg).
Taken together, these data suggest that AZD2461 might have two potential advantages over olaparib. First, while having a similar level of anti-tumor activity, AZD2461 did not have the same level of P-gp liability as olaparib; second, AZD2461 appeared better tolerated in combination with a DNA-damaging chemotherapy. The basis for this latter observation, though, could not obviously be attributed to PARP1/PARP2 inhibition, as AZD2461 and olaparib are similar in this respect, suggesting an as yet unidentified mechanism.
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AZD2461 and olaparib have differential activity against PARP3
One possible explanation for the hematological toxicity differences observed between olaparib and AZD2461 could be differential PARP3 activity. The PARP3 protein plays an important role in non-homologous end joining (NHEJ), where it is stimulated by DSBs in vitro and it functions in the same pathway as the PAR-binding protein APLF to accelerate chromosomal DSB repair (32) . Following IR treatment, phosphorylated histone H2AX (H2AX) can be used as a marker of DSB damage (42, 43) . The repair of DSBs and the decline in H2AX over time following IR was abrogated by either the loss of PARP3, APLF, or treatment with the PARP inhibitor KU-58948, which is related chemically to olaparib (32) .
The link between PARP3, NHEJ, and mouse bone marrow was highlighted in studies of murine hematopoietic stem and multipotent progenitor cells (HSPCs), which were shown to be more resistant to IR-induced damage than more differentiated progenitor cells (44) . This difference was based on both an increased resistance to apoptosis and the ability to repair DNA by NHEJ. The NHEJ pathway is a less reliable alternative to HRR DSB repair, and mice bone marrow stem cells appear to utilize NHEJ while human HSPCs undergo apoptosis in response to a DNA damage insult instead (45) . It has been suggested that the different ways the hematopoietic cells from mice and humans handle DNA damage may reflect the different challenges faced by mammals with diverse life spans and ages of reproductive maturity (46) .
To investigate whether differential PARP3 activity could provide the basis for the differential hematological toxicity observed with olaparib and AZD2461 in mice, we looked at the effect of both of these PARP inhibitors on H2AX following IR treatment (Fig. 4A) . Unlike olaparib, which results in persistence of H2AX following IR to the same degree as APLF knockdown, AZD2461 had no effect on H2AX dynamics. To confirm if this observation was due to PARP3 inhibition, we carried out PARP3 enzyme inhibition assays where PARP3 auto-ADP-ribosylation activity was assessed following the addition of increasing doses (2.5 nM-1.5 M) of olaparib or AZD2461. Fig. 4B shows that AZD2461 did not inhibit PARP3 to the same extent as olaparib. There was a 50-fold difference in PARP3 activity, with the IC50 value for PARP3 being 4 nM for olaparib and 200 nM for AZD2461 (Fig. 4B) . The data in Fig. 4A , C, and D suggest this difference at the enzyme level is sufficient to translate into a failure to inhibit NHEJ DSB repair, based on H2AX kinetics.
Increased bone marrow tolerability of AZD2461 in combination with temozolomide is mouse specific and is not seen in rat models
The finding that AZD2461 does not inhibit PARP3, coupled with previous studies that suggest mouse bone marrow HSPCs preferentially use NHEJ when dealing with DNA damage, suggests the observation of better tolerability of chemotherapy combination reported here could be specific to mice and not translate into humans. Prior to initiating clinical trials to test whether AZD2461 was better tolerated with chemotherapy than olaparib, we looked to repeat the experiment presented in Fig. 3 but in an athymic rat model. First we assessed PARP3 levels (and compared with PARP1 and PARP2 levels) in HSPCs from mice, rats, and humans ( Fig. 5 and Suppl Fig. 6 and Suppl Fig. 7) . We found that PARP3 levels were about 3.7 times higher in mice than in rats (Fig. 5A) , consistent with their use of NHEJ as a primary repair mechanism. Because of a lack of the same sequence identity, it was not possible to directly compare levels of PARP3 expression across mice, rats, and human bone marrow cells using the TaqMan probe-based assay. However, using SYBR green dye detection RT-PCR, we designed specific primers for human and rat PARP3 and demonstrated 20 that the relative level of PARP3 expression is very similar between rat and human bone marrow cells (Fig. 5B) .
In order to increase confidence around the finding of better hematological tolerability, we repeated the temozolomide combination study depicted in Fig. 3C in an athymic rat model (Fig. 5C) . Contrary to the result we obtained in mice, we observed that AZD2461 was no better tolerated than olaparib in terms of bone marrow toxicity (Fig. 5C) or total body weight loss (Suppl Fig. 5B and Suppl Fig. 5C) . A repeat of this experiment in male athymic rats (data not shown) confirmed these results. This observed difference could not obviously be explained by differences in PK between mice and rats, as they are comparable (10 mg/kg in both cases giving an area under the curve [AUCt] of 1-2 mol.h/L).
Here, we have provided an explanation for the better tolerability observed in mice by providing data showing the differential PARP3 activity for olaparib and AZD2461, and the different impact of the two compounds on NHEJ DSB repair as inferred by the effects on the recovery of radiation-induced H2AX. To date, technical challenges around the isolation and analysis of rat HSPCs have prevented us from directly demonstrating that rats are different from mice in utilizing NHEJ and therefore we cannot formally rule out alternative reasons for combination toxicity differences observed between the two rodent species. However, the clinical experience of combining PARP inhibitors with temozolomide (41) does argue that rat and not mouse is the better predictive model.
Structural analysis of the PARP3 active site
Previous studies have made the observation that PARP3 differs from PARP1 and PARP2 in the D-loop structure within the catalytic domain (47) . A sequence alignment of this region (Fig. 6 , Suppl Materials and Methods) shows that PARP3 contains a shorter loop within this region versus PARP1 and PARP2. A graphical model of the PARP3 crystal structure bound to PARP inhibitor KU58948 is shown in Fig. 6 ,see also (47) , with the variant region highlighted. The model shows that PARP3 may be more restrictive for binding by PARP inhibitors with charged or extended groups beyond the carbonyl linker region of these molecules, whereas the PARP1 and PARP2 structures have a more extended D-loop and may be more permissive for inhibitor binding. preparations can activate PARP1, and it has been suggested that PARP3 plays a role in regulating the DNA damage response through PARP1 activation (48) . However, our study shows that in cells treated with AZD2461, PARP3 is active in the NHEJ pathway even in the absence of detectable PARP1 activity, suggesting that the roles of PARP1 and PARP3 in chromosomal DNA repair are, in fact, independent. Second, the structural similarity between olaparib and AZD2461 that results in this observed differential activity against PARP3 has allowed a rationalization of the mechanistic basis of this difference in specificity via the modeling of the PARP inhibitors in the PARP3 active site. 22 An increase in our understanding of inhibitor-PARP family member interactions, as demonstrated by an independent study (49) , will also facilitate our understanding of PARP family biology. Together, advances in both an ability to generate inhibitors with a particular PARP specificity profile, as has been demonstrated very recently (50) , along with an understanding of the biological roles of the different PARP family members, should provide the opportunity to generate inhibitors with the optimal PARP inhibitory profile to maximize anti-tumor activity and therapeutic index. Rat average Ct was used as the reference level to calculate fold change differentials for each sample (biological n = 6). A two-tailed t-test with Welch's correlation was applied to analyze differences between gene expression in rat versus human tissue (PARP3 means difference -0.01548, p=0.9232). Box-and-whiskers graphs show mean from three experimental repeats.
analysis as in Fig. 3C . The graph represents the mean ± SD of total nucleated cell population (% of parent) in individual treatment groups (n = 3). 
